PCVXVaxcytePCVX info
$116.54info-0.18%24h
Global rank1451
Market cap$11.09B
Change 7d45.95%
YTD Performance87.94%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Vaxcyte (PCVX) Stock Overview

    Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

    PCVX Stock Information

    Symbol
    PCVX
    Address
    825 Industrial RoadSan Carlos, CA 94070United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://vaxcyte.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 837 0111

    Vaxcyte (PCVX) Price Chart

    -
    Value:-

    Vaxcyte Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $116.54
    N/A
    Market Cap
    $11.09B
    N/A
    Shares Outstanding
    95.15M
    N/A
    Employees
    158.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org